Bio-Rad Laboratories AI Stock Analysis
Want to see BIO full AI Analyst Report?
Bio-Rad Laboratories (BIO) AI Stock Analysis
Bio-Rad Laboratories
(NYSE:BIO)
The score is primarily driven by solid financial quality (notably a conservative balance sheet) alongside improving TTM profitability and cash generation, but tempered by historically volatile earnings and uneven free-cash-flow momentum. Technicals add support with an uptrend and moderate momentum, while valuation is favorable due to a low P/E. The earnings call is a modest headwind given negative-to-flat revenue guidance and persistent Life Science/China and logistics pressures despite improving margins and reaffirmed cash-flow outlook.
Bio-Rad Laboratories Key Performance Indicators (KPIs)
Revenue by SegmentAnalyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might focus future efforts.
Clinical Diagnostics has become the stable growth engine—sequential recovery and ddPCR/Stilla momentum are real and underpin recent margin improvement—while Life Science remains a multiyear soft spot, hurt by China order timing, weak consumable pull‑through and lumpy process‑chromatography demand. Other Operations is effectively negligible/exit‑level, removing a minor revenue tail. Management’s restructuring and buyback should lift margins, but top‑line upside hinges on consumables recovery and China normalizing; guidance still allows modest contraction, so a durable revenue inflection isn’t yet guaranteed.
Bio-Rad Laboratories (BIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.63B
- Dividend Yield
- ―
- Average Volume (3M)
- 255.67K
- Price to Earnings (P/E)
- 9.4
- Beta (1Y)
- 0.81
- Revenue Growth
- 1.38%
- EPS Growth
- ―
- Country
- US
- Employees
- 7,450
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Bio-Rad Laboratories Business Overview & Revenue Model
Company Description
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, an...
How the Company Makes Money
Bio-Rad makes money primarily by selling products and services across its two operating segments (Life Science and Clinical Diagnostics). Revenue is largely generated from (1) instrument sales (e.g., laboratory and diagnostic systems), which can be h...
Bio-Rad Laboratories Earnings Call Summary
The call conveyed cautious optimism. Bio-Rad highlighted a return to modest currency-neutral revenue growth, improving non-GAAP margins, strong ddPCR instrumentation, Diagnostics growth, product launches and ongoing restructuring and innovation initiatives. However, these positives were offset by declining total Life Science revenue, weak academic and government funding, China pricing pressure, logistics disruption, an expected fourth-quarter margin decline, negative-to-flat full-year revenue guidance and GAAP losses driven by restructuring and impairment charges. Management expects positive but not fully normalized growth in 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Bio-Rad reaffirmed full year '26 currency-neutral revenue growth between minus 3% and plus 0.5%, with full year growth expected to be approximately at the midpoint of this range; Life Science segments currency-neutral revenue growth is expected to be between minus 3% and minus 1%, and Clinical Diagnostics segment's currency-neutral revenue growth between minus 3% and plus 1%. Q4 revenue is expected to ramp up 5% to 6% on a reported basis, full year non-GAAP gross margin is expected in the upper half of the guidance range of between 53% and 54%, and full year non-GAAP operating margin in the upper half of the guidance range of between 10% and 12%; Q4 SG&A is expected to be flat to Q3, R&D to step up $3 million sequentially, and depreciation and amortization to be approximately $40 million. Full year 2026 free cash flow is expected to be in the range of approximately $290 million to $340 million. Management is focused on driving towards positive growth rate in '27 and driving further margin expansion in '27; it estimated the National Healthcare Security Administration guidelines' revenue impact in the middle single-digit millions of dollars in 2027, expects logistics disruption to continue into 2027, and expects $30 million, $35 million in restructuring savings, with full realization starting in '28.
Bio-Rad Laboratories Financial Statement Overview
Summary
Strong balance sheet (low leverage, large equity base) supports resilience, while TTM results show a rebound in revenue growth and a return to profitability with healthy gross margins. The main constraint is multi-year volatility in earnings and uneven cash-flow momentum (recent FCF growth negative and cash conversion variability), which lowers confidence in durability.
Income Statement
62PositiveBalance Sheet
82Very PositiveCash Flow
66Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.59B | 2.58B | 2.57B | 2.67B | 2.80B | 2.92B |
| Gross Profit | 1.33B | 1.34B | 1.38B | 1.43B | 1.57B | 1.64B |
| EBITDA | 1.48B | 1.21B | -2.14B | -654.80M | -4.53B | 5.59B |
| Net Income | 1.02B | 759.90M | -1.84B | -637.32M | -3.63B | 4.25B |
Balance Sheet | ||||||
| Total Assets | 10.78B | 10.58B | 9.36B | 12.30B | 13.50B | 17.80B |
| Cash, Cash Equivalents and Short-Term Investments | 1.66B | 1.54B | 1.66B | 1.61B | 1.79B | 869.92M |
| Total Debt | 1.36B | 1.53B | 1.37B | 1.41B | 1.39B | 223.38M |
| Total Liabilities | 3.18B | 3.12B | 2.79B | 3.56B | 3.89B | 4.11B |
| Stockholders Equity | 7.60B | 7.45B | 6.57B | 8.74B | 9.62B | 13.69B |
Cash Flow | ||||||
| Free Cash Flow | 329.10M | 374.60M | 266.20M | 218.26M | 80.29M | 535.72M |
| Operating Cash Flow | 468.10M | 532.20M | 455.20M | 374.94M | 194.45M | 669.46M |
| Investing Cash Flow | -340.00M | -189.70M | -160.20M | 20.21M | -1.21B | -797.38M |
| Financing Cash Flow | -70.20M | -283.20M | -218.80M | -425.65M | 973.58M | -55.43M |
Bio-Rad Laboratories Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Neutral. The current price of 358.19 is below the 20-day moving average (MA) of 373.84, below the 50-day MA of 372.00, and above the 200-day MA of 317.63, indicating a neutral trend. The MACD of -0.61 indicates Positive momentum. The RSI at 41.16 is Neutral, neither overbought nor oversold. The STOCH value of 22.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIO.
Bio-Rad Laboratories Risk Analysis
Bio-Rad Laboratories disclosed 28 risk factors in its most recent earnings report. Bio-Rad Laboratories reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskBio-Rad Laboratories Peers Comparison
Overall Rating
GKOS75Outperform
BIO71Outperform
NEOG61Neutral
BRKR57Neutral
CTKB53Neutral
QTRX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $14.40B | -83.03 | -24.91% | ― | 46.94% | -89.79% | |
| 71Outperform | $9.73B | 9.41 | 14.07% | ― | 1.38% | ― | |
| 61Neutral | $2.38B | -43.11 | -2.68% | ― | -0.33% | 94.64% | |
| 57Neutral | $9.37B | -55.94 | -5.15% | 0.33% | 2.16% | -604.24% | |
| 53Neutral | $745.47M | -9.02 | -24.74% | ― | 5.50% | -524.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | $135.79M | -1.21 | -42.99% | ― | 13.78% | -1.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIO | Bio-Rad Laboratories | 358.19 | 54.58 | 17.98% | |
| BRKR | Bruker Corporation | 61.36 | 17.71 | 40.56% | |
| NEOG | Neogen | 10.90 | 5.49 | 101.48% | |
| GKOS | Glaukos Corp. | 243.25 | 148.05 | 155.51% | |
| QTRX | Quanterix | 2.86 | -3.05 | -51.61% | |
| CTKB | Cytek Biosciences, Inc. | 5.70 | 0.49 | 9.40% |
Bio-Rad Laboratories Corporate Events
Bio-Rad Reports Third-Quarter Results and Improved Profitability
PositiveOn November 4, 2026, Bio-Rad reported third-quarter net sales of $656.4 million, up 0.5% from $653.0 million a year earlier. Currency-neutral sales increased 0.7%, led by a 2.8% currency-neutral gain in Clinical Diagnostics, while Life Science sales...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
